Develops therapies for central nervous system (CNS) disorders, focusing on pain management and treatment.
Relmada Therapeutics, Inc. is a dynamic clinical-stage biotechnology firm dedicated to advancing a diverse portfolio of treatments for central nervous system (CNS) diseases and related disorders. At the forefront of its development efforts is Esmethadone (d-methadone, dextromethadone, and REL-1017), a novel N-methyl-D-aspartate receptor antagonist currently undergoing Phase 3 clinical trials. Esmethadone is positioned as a potential breakthrough therapy for adults suffering from major depressive disorder, both as adjunctive therapy and as a standalone treatment.
Founded in 2004 and headquartered in Coral Gables, Florida, Relmada Therapeutics leverages cutting-edge research and clinical expertise to address significant unmet needs in CNS medicine. Beyond its leading candidate, the company continues to explore and develop innovative therapeutic solutions aimed at improving outcomes for patients affected by a range of neurological conditions.
Through strategic partnerships and a commitment to rigorous scientific innovation, Relmada Therapeutics is poised to make a meaningful impact in the field of CNS therapeutics. The company's pioneering approach reflects its mission to enhance the quality of life for individuals grappling with complex neurological disorders globally.